An Open-Label, Randomized, Multicenter, Phase II, Non Comparative, Exploratory Study on Neoadjuvant Treatment With Trastuzumab Plus Docetaxel Plus Bevacizumab According to Positon Emission Tomography (PET) Value Modification in Patients With Early Stage HER2 Positive Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel; Trastuzumab
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms AVATAXHER
- Sponsors Roche
- 20 Jul 2017 Planned End Date changed from 1 Nov 2017 to 31 Jan 2018.
- 20 Jul 2017 Planned primary completion date changed from 1 Nov 2017 to 31 Jan 2018.
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.